The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology
MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
NCP Cross, T Ernst, S Branford, JM Cayuela… - Leukemia, 2023 - nature.com
From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …
Chronic myeloid leukemia stem cells
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
S Branford, P Wang, DT Yeung… - Blood, The Journal …, 2018 - ashpublications.org
Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are
poorly understood. We performed whole-exome sequencing, copy-number variation, and/or …
poorly understood. We performed whole-exome sequencing, copy-number variation, and/or …
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
A Andrades, P Peinado, JC Alvarez-Perez… - Molecular cancer, 2023 - Springer
Hematological malignancies are a highly heterogeneous group of diseases with varied
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
molecular and phenotypical characteristics. SWI/SNF (SWItch/Sucrose Non-Fermentable) …
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved
due to advances in drug development and rational treatment intervention strategies. Despite …
due to advances in drug development and rational treatment intervention strategies. Despite …
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
Blast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML).
Although additional genetic alterations play a central role in BC, the landscape and …
Although additional genetic alterations play a central role in BC, the landscape and …